Susan VanMeter

740 total citations
16 papers, 511 citations indexed

About

Susan VanMeter is a scholar working on Neurology, Epidemiology and Pharmacology. According to data from OpenAlex, Susan VanMeter has authored 16 papers receiving a total of 511 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Neurology, 5 papers in Epidemiology and 3 papers in Pharmacology. Recurrent topics in Susan VanMeter's work include Parkinson's Disease Mechanisms and Treatments (4 papers), Multiple Sclerosis Research Studies (3 papers) and Neurological disorders and treatments (3 papers). Susan VanMeter is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (4 papers), Multiple Sclerosis Research Studies (3 papers) and Neurological disorders and treatments (3 papers). Susan VanMeter collaborates with scholars based in United States, United Kingdom and Canada. Susan VanMeter's co-authors include Jack G. Modell, Carol B. Rockett, Michael E. Thase, Barbara R. Haight, Nathalie Richard, Amit Bar‐Or, Richard Grove, Daren Austin, Sarah Kavanagh and Jerry M. Tolson and has published in prestigious journals such as Gastroenterology, Neurology and The Journal of Clinical Psychiatry.

In The Last Decade

Susan VanMeter

12 papers receiving 486 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susan VanMeter United States	8	172	133	113	96	93	16	511
Richard Leigh-Pemberton United States	7	150 0.9×	137 1.0×	28 0.2×	33 0.3×	44 0.5×	12	492
Nicolás Schmidt Uruguay	8	51 0.3×	64 0.5×	41 0.4×	52 0.5×	92 1.0×	20	512
Huiqin Xu China	16	37 0.2×	29 0.2×	230 2.0×	40 0.4×	51 0.5×	53	641
Katrin Pape Germany	8	26 0.2×	134 1.0×	65 0.6×	82 0.9×	102 1.1×	18	619
Aisling M. Chaney United States	12	56 0.3×	17 0.1×	32 0.3×	58 0.6×	56 0.6×	22	593
Enrico D’Ambrosio Italy	16	74 0.4×	26 0.2×	236 2.1×	14 0.1×	94 1.0×	38	746
Kevin M. Bellew United States	13	176 1.0×	60 0.5×	148 1.3×	15 0.2×	20 0.2×	27	892
Taku Sato Japan	12	158 0.9×	75 0.6×	48 0.4×	47 0.5×	12 0.1×	42	617
Ken Gordon United States	9	86 0.5×	93 0.7×	153 1.4×	551 5.7×	13 0.1×	24	1.2k
Luca Ausili Cefaro Italy	7	205 1.2×	173 1.3×	22 0.2×	72 0.8×	116 1.2×	10	416

Countries citing papers authored by Susan VanMeter

Since Specialization

Citations

This map shows the geographic impact of Susan VanMeter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan VanMeter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan VanMeter more than expected).

Fields of papers citing papers by Susan VanMeter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan VanMeter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan VanMeter. The network helps show where Susan VanMeter may publish in the future.

Co-authorship network of co-authors of Susan VanMeter

This figure shows the co-authorship network connecting the top 25 collaborators of Susan VanMeter. A scholar is included among the top collaborators of Susan VanMeter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan VanMeter. Susan VanMeter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Domínguez‐González, Cristina, Carl Chiang, Anny‐Odile Colson, et al.. (2025). Pyrimidine Nucleos(t)ide Therapy in Patients With Thymidine Kinase 2 Deficiency. Neurology. 105(6). e213908–e213908.

Hirano, Michio, A. Nascimento Osorio, Yuanjun Ma, et al.. (2025). The Disease Course of Untreated Patients with Thymidine Kinase 2 Deficiency (TK2d) Aged ≤12 Years at TK2d Symptom Onset: Findings from the Largest International TK2d Dataset (P10-6.007). Neurology. 104(7_Supplement_1).

Domínguez‐González, Cristina, A. Nascimento Osorio, Yuanjun Ma, et al.. (2025). The Disease Course of Untreated Patients with Thymidine Kinase 2 Deficiency (TK2d) Aged >12 Years at TK2d Symptom Onset: Findings from the Largest International TK2d Dataset (P2-11.020). Neurology. 104(7_Supplement_1).

VanMeter, Susan, et al.. (2024). Pharmacokinetics and Safety of a 1:1 Mixture of Doxecitine and Doxribtimine: Open-label Phase 1 Single Ascending Dose and Food Effect Studies in Healthy Adults. Clinical Therapeutics. 46(7). 576–587.

VanMeter, Susan, et al.. (2021). Prevalence of Hepatic Encephalopathy from a Commercial Medical Claims Database in the United States. International Journal of Hepatology. 2021. 1–6. 9 indexed citations

VanMeter, Susan, et al.. (2018). Post hoc analysis using PRO-ACT database to evaluate Repository Corticotropin Injection (H.P. Acthar® Gel) as a potential treatment for ALS (P5.327). Neurology. 90(15_supplement). 2 indexed citations

Bar‐Or, Amit, Richard Grove, Daren Austin, et al.. (2018). Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis. Neurology. 90(20). e1805–e1814. 154 indexed citations

Zesiewicz, Theresa A., et al.. (2017). A randomized, fixed-dose, dose–response Study of Ropinirole Prolonged Release in Advanced Parkinson’s Disease. Neurodegenerative Disease Management. 7(1). 61–72. 12 indexed citations

Zesiewicz, Theresa, et al.. (2017). A fixed-dose, dose–response Study of Ropinirole Prolonged Release in Early Stage Parkinson’s Disease. Neurodegenerative Disease Management. 7(1). 49–59. 7 indexed citations

10.

Ellis, Jeffrey J., et al.. (2014). Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease. International Journal of Neuroscience. 126(1). 30–38. 9 indexed citations

11.

Bar‐Or, Amit, et al.. (2014). The MIRROR Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and MRI Efficacy of Subcutaneous Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) (S23.006). Neurology. 82(10_supplement). 22 indexed citations

12.

Bar‐Or, Amit, et al.. (2014). The MIRROR Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and MRI Efficacy of Subcutaneous Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) (I7-1.007). Neurology. 82(10_supplement). 3 indexed citations

13.

Buckley, Jessie P., Michael D. Kappelman, Jeffery K. Allen, Susan VanMeter, & Suzanne F. Cook. (2013). Su1057 The Burden of Comedication Among Inflammatory Bowel Disease Patients. Gastroenterology. 144(5). S–388. 1 indexed citations

14.

VanMeter, Susan, et al.. (2012). Dose Response of Gabapentin Enacarbil versus Placebo in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome. CNS Drugs. 26(9). 773–780. 15 indexed citations

15.

Jefferson, James W., A. John Rush, J. Craig Nelson, et al.. (2006). Extended-Release Bupropion for Patients With Major Depressive Disorder Presenting With Symptoms of Reduced Energy, Pleasure, and Interest. The Journal of Clinical Psychiatry. 67(6). 865–873. 42 indexed citations

16.

Thase, Michael E., Barbara R. Haight, Nathalie Richard, et al.. (2005). Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors. The Journal of Clinical Psychiatry. 66(8). 974–981. 235 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact